Bionano Genomics (BNGO) Near Publishing Cytogenetics Results, Oppenheimer Would Buy Ahead of Earnings
Tweet Send to a Friend
Oppenheimer analyst Kevin DeGeeter reiterated an Outperform rating and $1.50 price target on Bionano Genomics (NASDAQ: BNGO) suggesting investors buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
